<DOC>
	<DOCNO>NCT02697669</DOCNO>
	<brief_summary>Heart failure clinical syndrome exercise intolerance and/or congestion . The potential role myocardial perfusion metabolic abnormality subject cardiovascular risk , metabolic disease heart failure assess nuclear dynamic imaging warrant investigation . The study investigator propose microvascular dysfunction abnormal metabolic substrate shift precede trigger onset diastolic dysfunction . The aim ( 1 ) develop validate noninvasive measurement absolute myocardial blood flow ( MBF ) myocardial flow reserve ( MFR ) use dynamic imaging CZT camera , ( 2 ) ass myocardial glucose metabolism use 18F-FDG dynamic PET , MBF , MFR LV systolic diastolic function dynamic SPECT comprehensively subject cardiovascular risk metabolic disease , HFrEF HFpEF , ( 3 ) correlate peripheral serum marker blood mononuclear cell subsets myocardial perfusion metabolic abnormality , ( 4 ) test hypothesis image blood marker diagnosis prognostic implication . The study investigator also assess myocardial metabolic utilization healthy mouse model different metabolic disorder ( obesity , diabetes mellitus hypertension ) use 18F-FDG dynamic micro PET/CT , in-vivo measure could use well understanding disease mechanism evaluate therapeutic strategy .</brief_summary>
	<brief_title>The Role Nuclear Imaging Heart Failure</brief_title>
	<detailed_description>Heart failure ( HF ) clinical syndrome exercise intolerance and/or congestion . The management heart failure reduce ejection fraction ( HFrEF ) improve last decade . In contrast , little progress make identify evidence-based , effective treatment heart failure preserve ejection fraction ( HFpEF , LVEF &gt; 50 % ) . Treatments proven effective HFrEF fail show significant benefit patient HFpEF . Potential contributor include incomplete understanding pathophysiology poor match therapeutic mechanism . The challenge use diagnostic criterion , prognostic evaluation treatment highlight need research field . This portion HFpEF consist predominantly old age high prevalence co-morbidity overweight/obesity , diabetes mellitus , hyperlipidemia , metabolic syndrome hypertension . The systemic pro-inflammatory state may induce coronary endothelial inflammation , microvasular dysfunction , myocardial substrate shift , myocardial interstitial fibrosis contribute high diastolic leave ventricular stiffness HF development . Myocardial metabolic perfusion image vital tool understand physiologic consequence HF . Absolute myocardial blood flow ( MBF ) myocardial flow reserve ( MFR ) provide incremental diagnostic prognostic information relative perfusion alone . Recent development dedicate cardiac SPECT camera well sensitivity temporal resolution make dynamic SPECT image practical . Quantitative 18F-FDG PET could use mean measure myocardial metabolic change . The study investigator propose microvasular dysfunction abnormal metabolic substrate shift precede trigger onset diastolic dysfunction . The potential role myocardial perfusion metabolic abnormality subject cardiovascular risk , metabolic disease HFpEF assess nuclear dynamic imaging warrant investigation . The present project aim ( 1 ) develop validate noninvasive measurement absolute myocardial blood flow ( MBF ) myocardial flow reserve ( MFR ) use dynamic imaging CZT camera , ( 2 ) ass myocardial glucose metabolism use 18F-FDG dynamic PET , MBF , MFR LV systolic diastolic function dynamic SPECT comprehensively participants cardiovascular risk metabolic disease , HFrEF HFpEF , ( 3 ) correlate peripheral serum marker blood mononuclear cell subsets myocardial perfusion metabolic abnormality , ( 4 ) test hypothesis image blood marker diagnosis prognostic implication . The study investigator also assess myocardial metabolic utilization healthy mouse model different metabolic disorder ( obesity , diabetes mellitus hypertension ) use 18F-FDG dynamic micro PET/CT , in-vivo measure could use well understanding disease mechanism evaluate therapeutic strategy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Had clinical diagnosis heart failure leave ventricular systolic function ( LVEFâ‰¤50 % ) diastolic dysfunction , 2 . Clinical diagnosis metabolic disease ( metabolic syndrome , obesity , diabetes , hyperlipidemia , microvascular disease etc . ) , heart failure highrisk group . 1 . Important systemic disease ( except heart disease ) cirrhosis , endstage renal disease active malignancy estimate life expectancy less three month . 2. pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>myocardial perfusion</keyword>
	<keyword>single-photon emission tomography</keyword>
</DOC>